Redeye comments on Faron’s updated BEXMAB data presented at the ESMO 2025 congress, which further strengthens the clinical and mechanistic foundation of bexmarilimab in high-risk myelodysplastic syndrome (HR-MDS). The data showed an improved 85% overall response rate and 45% complete remission rate in treatment-naïve patients, alongside a clear pharmacodynamic correlation between Clever-1 target engagement and clinical outcomes.
LÄS MER
